Kymera Therapeutics (KYMR) Misses Q2 EPS by 8c

Kymera Therapeutics (NASDAQ: KYMR) reported Q2 EPS of ($0.78), $0.08 worse than the analyst estimate of ($0.70). Revenue for the quarter came in at $11.51 million versus the consensus estimate of $13.84 million.

For earnings history and earnings-related data on Kymera Therapeutics (KYMR) click here.

You May Also Be Interested In

• Jefferies upgrades Shopify to Buy on AI commerce tailwinds, sees 30% upside
• JD.com, Inc (JD) PT Lowered to $37 at Macquarie ahead of earnings
• Freedom Holding raises $300M in share offering at $126.35 per share